TCM
BEAM icon

Tradewinds Capital Management’s Beam Therapeutics BEAM Stock Holding History

Tradewinds Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-50
Closed -$3K – 461
2022
Q1 		$3K Hold
50
– – ﹤0.01% 614
2021
Q4 		$4K Hold
50
– – ﹤0.01% 599
2021
Q3 		$4K Hold
50
– – ﹤0.01% 576
2021
Q2 		$6K Hold
50
– – ﹤0.01% 539
2021
Q1 		$4K Hold
50
– – ﹤0.01% 564
2020
Q4 		$4K Buy
+50
New +$2.46K ﹤0.01% 524

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Tradewinds Capital Management's BEAM Position: Q2 2022 in Review

Tradewinds Capital Management sold out of Beam Therapeutics (BEAM) in Q2 2022, closing a stake of 50 shares — an estimated $3K sold.

Tradewinds Capital Management first reported a position in BEAM in Q4 2020 and held it in 6 quarters. The position peaked at $6K in Q2 2021. 205 funds tracked by Wall St. Rank hold BEAM as of Q2 2022.

  • Tradewinds Capital Management reported no remaining Beam Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Tradewinds Capital Management sold 50 Beam Therapeutics shares in Q2 2022, an estimated $3K.
  • Tradewinds Capital Management first reported a position in Beam Therapeutics in Q4 2020 and held it in 6 quarters.
  • Tradewinds Capital Management's Beam Therapeutics position peaked at $6K in Q2 2021.
  • 205 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2022.

Based on Tradewinds Capital Management's 13F filing for Q2 2022, filed 21 Jul 2022.